295 related articles for article (PubMed ID: 16499130)
1. New approaches to preventing xerostomia.
J Support Oncol; 2006 Feb; 4(2):87-8. PubMed ID: 16499130
[No Abstract] [Full Text] [Related]
2. Evaluation, prevention and management of radiotherapy-induced xerostomia in head and neck cancer patients.
de Castro G; Federico MH
Curr Opin Oncol; 2006 May; 18(3):266-70. PubMed ID: 16552239
[TBL] [Abstract][Full Text] [Related]
3. Preventing radiation induced xerostomia.
Koukourakis MI; Danielidis V
Cancer Treat Rev; 2005 Nov; 31(7):546-54. PubMed ID: 16257125
[TBL] [Abstract][Full Text] [Related]
4. Management of salivary hypofunction during and after radiotherapy.
Shiboski CH; Hodgson TA; Ship JA; Schiødt M
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Mar; 103 Suppl():S66.e1-19. PubMed ID: 17379158
[TBL] [Abstract][Full Text] [Related]
5. Pathophysiology and management of radiation-induced xerostomia.
Berk LB; Shivnani AT; Small W
J Support Oncol; 2005; 3(3):191-200. PubMed ID: 15915820
[TBL] [Abstract][Full Text] [Related]
6. Management of xerostomia related to radiotherapy for head and neck cancer.
Kahn ST; Johnstone PA
Oncology (Williston Park); 2005 Dec; 19(14):1827-32; discussion 1832-4, 1837-9. PubMed ID: 16506635
[TBL] [Abstract][Full Text] [Related]
7. Artificial saliva products and drugs to treat xerostomia.
Wynn RL; Meiller TF
Gen Dent; 2000; 48(6):630-6. PubMed ID: 12004654
[No Abstract] [Full Text] [Related]
8. Toxicity and compliance of subcutaneous amifostine in patients undergoing postoperative intensity-modulated radiation therapy for head and neck cancer.
Thorstad WL; Chao KS; Haughey B
Semin Oncol; 2004 Dec; 31(6 Suppl 18):8-12. PubMed ID: 15726516
[TBL] [Abstract][Full Text] [Related]
9. [Future therapy strategies for salivary gland impairment].
Aframian DJ; Palmon A; Nahlieli O
Refuat Hapeh Vehashinayim (1993); 2004 Jul; 21(3):43-50, 93. PubMed ID: 15503981
[TBL] [Abstract][Full Text] [Related]
10. Radiotherapy-induced salivary dysfunction.
Ship JA; Hu K
Semin Oncol; 2004 Dec; 31(6 Suppl 18):29-36. PubMed ID: 15726520
[TBL] [Abstract][Full Text] [Related]
11. [Current status of prevention and management of radiation-induced xerostomia].
Ma DY; Qiu WL; Zhang CP
Zhonghua Kou Qiang Yi Xue Za Zhi; 2010 Feb; 45(2):121-3. PubMed ID: 20368009
[No Abstract] [Full Text] [Related]
12. Radiation-induced xerostomia: how dry is your patient?
Bruce SD
Clin J Oncol Nurs; 2004 Feb; 8(1):61-7. PubMed ID: 14983765
[TBL] [Abstract][Full Text] [Related]
13. In regard to Münter et Al. Changes in salivary gland function after radiotherapy of head and neck tumors measured by quantitative pertechnetate scintigraphy: comparison of intensity-modulated radiotherapy and conventional radiation therapy with and without amifostine. (Int j radiat oncol biol phys 2007;67:651-659).
Messerschmidt GL; Oleka N
Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1651-2; author reply 1652. PubMed ID: 18035221
[No Abstract] [Full Text] [Related]
14. Systemic pilocarpine for treatment of xerostomia.
Berk L
Expert Opin Drug Metab Toxicol; 2008 Oct; 4(10):1333-40. PubMed ID: 18798702
[TBL] [Abstract][Full Text] [Related]
15. Pilocarpine in the prevention of postirradiation xerostomia.
Lajtman Z; Krajina Z; Krpan D; Vincelj J; Borcić V; Popović-Kovacić J
Acta Med Croatica; 2000; 54(2):65-7. PubMed ID: 11028111
[TBL] [Abstract][Full Text] [Related]
16. The role of saliva in oral health: strategies for prevention and management of xerostomia.
Brosky ME
J Support Oncol; 2007 May; 5(5):215-25. PubMed ID: 17564151
[TBL] [Abstract][Full Text] [Related]
17. In regards to Münter et Al. (Int J Radiat Oncol Biol Phys 2007;67:651-659).
Samuels MA
Int J Radiat Oncol Biol Phys; 2007 Sep; 69(1):318; author reply 318-9. PubMed ID: 17707287
[No Abstract] [Full Text] [Related]
18. Preemptive pharmacologic intervention in radiation-induced salivary dysfunction.
Taylor SE; Miller EG
Proc Soc Exp Biol Med; 1999 May; 221(1):14-26. PubMed ID: 10320627
[TBL] [Abstract][Full Text] [Related]
19. Radioprotective effect of amifostine in patients with head and neck squamous cell carcinoma.
Bourhis J; Rosine D
Semin Oncol; 2002 Dec; 29(6 Suppl 19):61-2. PubMed ID: 12577247
[TBL] [Abstract][Full Text] [Related]
20. Preliminary data of the GORTEC 2000-02 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapy.
Bardet E; Martin L; Calais G; Tuchais C; Bourhis J; Rhein B; Feham N; Alphonsi M
Semin Oncol; 2002 Dec; 29(6 Suppl 19):57-60. PubMed ID: 12577246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
